Highlights PaxMedica, Inc.

Equities

PXMD

US70424C2035

Market Closed - OTC Markets Other stock markets 12:54:49 29/06/2024 am IST			5-day change	1st Jan Change
0.2176 ^USD	+0.99%		-1.76%	-71.25%

13/05	PaxMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	PaxMedica, Inc.(NasdaqCM:PXMD) dropped from S&P TMI Index	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

PaxMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Paxmedica, Inc. Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101	23/04	CI
PaxMedica, Inc. Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness	17/04	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	13/04	MT
Top Midday Gainers	12/04	MT
Major US Banks' Lower Earnings Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	12/04	MT
PaxMedica, Inc. Achieves Key Milestone in the Development of Pax-101 and Provides Update on Potential NDA Submission	12/04	CI
PaxMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
PaxMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11	CI
PaxMedica, Inc. acquired Certain Suramin Research Assets from Rediscovery Life Sciences AKI LLC for $0.1 million.	31/23/31	CI
Paxmedica, Inc. Holds Important Fda Type-B Meeting to Review Pax-101 Pivotal Trial Data	26/23/26	CI
PaxMedica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
PaxMedica, Inc. Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301	24/23/24	CI
PaxMedica, Vox Nova in Pharmacy Distribution Deal for PAX-101 in US	06/23/06	MT
PaxMedica, Inc. Submits Request to South African Health Products Regulatory Authority, Seeking Approval to Conduct Double-Blind, Placebo-Controlled Study, PAX-ASD-101	14/23/14	CI
PaxMedica, Inc. Enters Research Collaboration Agreement with PoloMar Health for Phase II Study in Autism Spectrum Disorder	09/23/09	CI
PaxMedica Signs Research Deal With PoloMar Health for Mid-Stage Autism Spectrum Disorder Trial	08/23/08	MT
PaxMedica, Inc. Completes Efficacy Review and Final Enrollment for the Company's Real World Evidence Study (HAT-301)	03/23/03	CI
PaxMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
PaxMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PaxMedica, Inc.

Equities

PXMD

US70424C2035

Highlights

Filters